AstraZeneca says Imfinzi combo shows promise in late-stage lung cancer trial By Reuters

(Reuters) – Drugmaker AstraZeneca (NASDAQ 🙂 said on Thursday its cancer drug Imfinzi, when given along with neoadjuvant chemotherapy in a late-stage trial, showed promise in helping patients with an aggressive form of lung cancer before surgery.

The combination showed a statistically significant and significant improvement in pathologic complete response compared with neoadjuvant chemotherapy alone in patients with resectable non-small cell lung cancer, the company said.